Artivion (AORT) to Release Earnings on Thursday

Artivion (NYSE:AORT) is expected to be issuing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $110.7120 million for the quarter. Artivion has set its FY 2025 guidance at EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.13. The business had revenue of $112.97 million during the quarter, compared to analyst estimates of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Stock Down 0.7%

NYSE:AORT opened at $44.94 on Thursday. The firm has a market cap of $2.12 billion, a P/E ratio of -107.00 and a beta of 1.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. Artivion has a fifty-two week low of $21.97 and a fifty-two week high of $45.83. The firm has a 50-day simple moving average of $42.15 and a two-hundred day simple moving average of $34.36.

Insider Activity at Artivion

In other news, insider John E. Davis sold 10,802 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the sale, the insider owned 208,778 shares of the company’s stock, valued at $9,117,335.26. This trade represents a 4.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO James P. Mackin sold 12,500 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $42.32, for a total transaction of $529,000.00. Following the sale, the chief executive officer directly owned 852,783 shares in the company, valued at approximately $36,089,776.56. The trade was a 1.44% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 74,858 shares of company stock worth $3,250,129. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Artivion

Institutional investors have recently made changes to their positions in the business. Marshall Wace LLP lifted its stake in shares of Artivion by 76.8% in the 2nd quarter. Marshall Wace LLP now owns 31,526 shares of the company’s stock worth $980,000 after purchasing an additional 13,698 shares during the period. Invesco Ltd. lifted its stake in shares of Artivion by 40.8% in the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after purchasing an additional 139,370 shares during the period. Public Sector Pension Investment Board lifted its stake in shares of Artivion by 9.5% in the 2nd quarter. Public Sector Pension Investment Board now owns 130,981 shares of the company’s stock worth $4,074,000 after purchasing an additional 11,331 shares during the period. Thrivent Financial for Lutherans lifted its stake in shares of Artivion by 20.4% in the 2nd quarter. Thrivent Financial for Lutherans now owns 33,366 shares of the company’s stock worth $1,038,000 after purchasing an additional 5,654 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its stake in shares of Artivion by 7.3% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 33,165 shares of the company’s stock worth $1,032,000 after purchasing an additional 2,253 shares during the period. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

AORT has been the subject of a number of analyst reports. JMP Securities raised their price objective on shares of Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research note on Friday, October 10th. LADENBURG THALM/SH SH lowered shares of Artivion from a “buy” rating to a “neutral” rating and raised their price objective for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. Canaccord Genuity Group raised their price target on shares of Artivion from $41.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 29th. Finally, Stifel Nicolaus raised their price target on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and an average price target of $43.97.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.